BioTechniques

Antibody–drug conjugates: a breakthrough in the targeted therapy era

Grace Liu (left) is a Technical Account Manager at Sino Biological US Inc. (PA, USA). Grace joined Sino Biological in 2022, supporting CRO services and project management in the western and central US ...
Medscape

Antibody–Drug Conjugates for the Treatment of B-cell Non–Hodgkin's Lymphoma and Leukemia

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the development ...

Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform -- Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ...
GEN

Reagents for Internalization Studies in Drug Discovery

Revvity has launched pHSense™ reagents, a plate-based technology designed to monitor receptor and antibody-drug conjugate (ADC) internalization in high-throughput workflows. The reagents use a ...
Nasdaq

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

ROCKVILLE, M.D. and SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
News Medical

A new era of targeted therapy with antibody–drug conjugates

In this interview, Grace Liu from Sino Biological shares her expertise on Antibody-Drug Conjugates (ADCs), a revolutionary cancer therapy combining precision targeting with potent cytotoxic drugs.